Developing modern vaccine adjuvants, particularly those involving the QS-21 molecule, is a complex and resource-intensive journey. The challenge for many R&D teams is the initial transition from raw extract to a workable, purified matrix.

In March 2026, Quillaja Green Biosolutions joined the global immunology community at the World Vaccine Congress in Washington D.C. Our participation focused on the evolving demand for high-purity saponin matrices and the critical role of secure, scalable supply chains for next-generation adjuvants.

In March 2026, Quillaja Green Biosolutions joined the global immunology community at the World Vaccine Congress in Washington D.C. Our participation focused on the evolving demand for high-purity saponin matrices and the critical role of secure, scalable supply chains for next-generation adjuvants.

In the production of Quillaja-based adjuvants and functional ingredients, the most critical phase occurs long before the laboratory extraction. Biological performance is not just a result of purification; it is a direct consequence of the raw material’s molecular integrity.